Methods and compositions for treating asthma and allergic diseases

A technology for allergic diseases and asthma, applied in the field of allergies, can solve problems such as no certain impact
CN112654397APending Publication Date: 2021-04-13INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4
18 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Publication Date
2021-04-13

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determine its impact on allergies and / or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+ / +) or PCSK9-deficient mice (PCSK9- / -) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer's patches. Moreover, inventors have shown the effect of allergic challenge on primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and / or allergic disease, such as food allergy.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of allergy. More specifically, the present invention relates to methods and compositions for the treatment of asthma and allergic diseases such as food allergies. Background technique

[0002] PCSK9 (proprotein convertase subtilisin kexin type 9) is a key regulator of cholesterol metabolism, and PCSK9 inhibitors have been developed to treat hypercholesterolemia and cardiovascular diseases.

[0003] PCSK9 was discovered in 2003 in patients with autosomal dominant hypercholesterolemia (1), and its canonical role as a natural inhibitor of the low-density lipoprotein receptor (LDLR) was quickly established (2). After autophagy in the endoplasmic reticulum, PCSK9 is secreted by the liver into a mature form in the blood. PCSK9 binds to the extracellular domain of LDLR and interferes with LDLR trafficking by promoting its lysosomal degradation rather than recycling to the membrane. Genetic studies have further dem...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More